Insights about U.S. Stocks that landed in the Red-Zone during Thursday’s trade, are depicted underneath:
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)’s shares dwindled -8.61%, and closed at $0.690. The stock volatility for the week is 26.89%, while for the month remained 14.45%. The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
AVEO Pharmaceuticals, Inc (NASDAQ:AVEO), declined -7.79%, and closed at $1.42.
AVEO Pharmaceuticals, Inc. (AVEO), declared that administration will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.m. Eastern Time to talk about the presentation of final results and a predefined biomarker analysis of its BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer. The presentation, titled “Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 as compared to bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial,” will be presented in a poster session on March 6 at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference in Orlando, FL.
The call can be accessed by dialing 1-877-280-4954 (domestic) or 1-857-244-7311 (international) five minutes preceding to the start of the call and providing the passcode 38640881. A replay of the call will be accessible two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 54500453. The replay will be accessible for two weeks from the date of the live call.
AVEO Oncology (AVEO) is a biopharmaceutical corporation committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where noteworthy unmet medical needs exist.
Bio-Reference Laboratories Inc (NASDAQ:BRLI), dipped -7.67%, and closed at $33.71.
Bio-Reference Laboratories Inc. (BRLI), declares first quarter results. Except for per share data or where otherwise noted, numbers are in thousands.
The Corporation recorded Q1FY15 proceeds of $208,833, an raise of 15% over the $181,270 recorded in Q1FY14. Net revenue before taxes in Q1FY15 totaled $11,504, an raise of 119% contrast with net revenue before taxes of $5,255 in Q1FY14. Net revenue after tax for Q1FY15 totaled $6,633, or $.24 per share, as contrast with $2,954, or $.11 per share, in Q1FY14. The Corporation noted in Q1FY14 that weather had accounted for a $.05 reduction in net revenue and any comparison with the preceding year ought to account for the bad weather adjustment. Gross profits on proceeds for Q1FY15 were $89,755, resulting in a margin for gross profit on proceeds of 43%, as compared to $72,154 for Q1FY14, which resulted in a margin of 40%. Proceed per patient for Q1FY15 was $88.09, an raise of 8% contrast to the $81.17 for Q1FY14. The number of patients served raised 7% to 2,352 in Q1FY15 from the Q1FY14 of 2,206. Esoteric business for the Corporation was 70% of proceeds for Q1FY15 as contrast to 66% of proceeds for Q1FY14. Days Sales Outstanding (DSO) was 113 days contrast to Q1FY14 DSO of 111 days. Cash Flow from Operations for Q1FY15 was slightly greater than $10,000.
Marc D. Grodman, MD, CEO, commented: “This is the first quarter in several years where we believe that one can make valid year over year quarterly comparison given the reset attributable to both the reimbursement changes we have seen as an industry in addition to our investment in our own infrastructure, both of which occurred in 2013. Our proceed for the quarter was up over 15%, with an raise in proceed per patient from $81.17 to $88.09 or a bit over 8%, consistent with our growth in all sequencing based testing. While much of this can be attributable to tests marketed under our GeneDx franchise, in reality, it comprises testing offered through both GenPath Oncology and Women’s Health, as well. Net Revenue for the quarter was $.24 as contrast to $.11 in the first quarter of the previous year, an raise of almost 125%. We are not ignoring the influence weather had on last year’s results. Given the benefit of the $.05 per share of earnings we estimated was lost due to inclement weather last year, we still would have shown an raise in earnings per share of 50%. Even further, this does not take into account the raise in legal fees due to the now settled BRCA related litigations, almost $.03 a share was attributable to these matters in the current first quarter over the preceding year same quarter.”
Bio-Reference Laboratories, Inc. is one of the largest and fastest growing full service diagnostic laboratories in the world, providing clinical testing services to physician offices, clinics, hospitals, long term care facilities and employers while also advancing drug discovery and development with disease foundations, academic and pharmaceutical partners. Our comprehensive testing capabilities and expertise spans molecular diagnostics, anatomical pathology, women’s health, oncology and rare disease genetics. Bio-Reference, and our auxiliaries, have an international presence in more than 50 countries.
Endocyte, Inc (NASDAQ:ECYT), dropped -7.13%, and closed at $6.25.
Endocyte, Inc. (ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, declared financial results for the fourth quarter ending December 31, 2014, and offered a clinical update.
Mike Sherman, chief operating officer and chief financial officer of Endocyte, commented, “We have done extensive work to define the optimal indications for the next phase of development for EC1456 in order to maximize the likelihood of success. Our aim is to secure efficacy and safety data by mid-year 2016 for at least two indications for EC1456, and for the expanded trial of EC1169. With more than $200 million in cash, we are in a strong position to advance theses agents into the next phase of development.”
Forthcoming Predictable Milestones:
- Final overall survival results from the TARGET trial of vintafolide in combination with docetaxel in NSCLC predictable to be declared in the second or third quarter of 2015.
- Completion of Phase 1 dose escalation trials for both EC1456 and EC1169, identifying the MTD and preferred plan for each agent. Safety and efficacy data predictable to be declared at a medical conference in 2015.
- Expansion of the trial for EC1456, which will evaluate the safety and efficacy of EC1456 at the MTD as a monotherapy and in drug combinations in patients with all target lesions positive for the folate receptor in NSCLC, triple-negative breast, ovarian and endometrial cancers. We expect to initiate this portion of the trial in the second half of 2015, and to reach tumor response endpoints in some indications by mid-year 2016.
- Expansion of the trial for EC1169, which will evaluate the safety and efficacy of EC1169 at the MTD in recurrent prostate cancer patients. We also expect to initiate this portion of the trial on the second half of 2015 and to reach primary endpoints by mid-2016.
The Corporation anticipates that its cash balance at the end of 2015 will exceed $155 million. Spending is predictable to raise from the first half of 2015 to the second half as the trials for EC1456 and EC1169 are expanded once the maximum tolerated doses are determined.
Endocyte is a biopharmaceutical corporation and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The corporation’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.
